Beam Therapeutics Inc. (BEAM)
Market Cap | 1.86B |
Revenue (ttm) | 360.91M |
Net Income (ttm) | -134.74M |
Shares Out | 82.31M |
EPS (ttm) | -1.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 880,753 |
Open | 22.90 |
Previous Close | 23.05 |
Day's Range | 22.25 - 23.00 |
52-Week Range | 16.95 - 49.50 |
Beta | 1.88 |
Analysts | Buy |
Price Target | 42.20 (+86.97%) |
Earnings Date | Aug 6, 2024 |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301,... [Read more]
Financial Performance
In 2023, BEAM's revenue was $377.71 million, an increase of 520.01% compared to the previous year's $60.92 million. Losses were -$132.53 million, -54.16% less than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is $42.2, which is an increase of 86.97% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/l/a/press9-2496906.jpg)
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the firs...
![](https://cdn.snapi.dev/images/v1/g/r/press20-2479210.jpg)
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting i...
![](https://cdn.snapi.dev/images/v1/o/i/conf7-2453174.jpg)
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gius...
![](https://cdn.snapi.dev/images/v1/n/w/conf2-2430581.jpg)
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
![](https://cdn.snapi.dev/images/v1/z/v/conf6-2417431.jpg)
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...
![](https://cdn.snapi.dev/images/v1/a/o/press19-2414057.jpg)
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated
![](https://cdn.snapi.dev/images/v1/a/m/press3-2341287.jpg)
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
![](https://cdn.snapi.dev/images/v1/h/9/conf12-2297937.jpg)
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
![](https://cdn.snapi.dev/images/v1/l/j/press18-2295285.jpg)
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024
![](https://cdn.snapi.dev/images/v1/w/a/press11-2259395.jpg)
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
![](https://cdn.snapi.dev/images/v1/g/v/press5-2219743.jpg)
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data ...
![](https://cdn.snapi.dev/images/v1/6/k/conf16-2212858.jpg)
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
![](https://cdn.snapi.dev/images/v1/m/6/press7-2195866.jpg)
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appo...
![](https://cdn.snapi.dev/images/v1/w/z/press8-2146291.jpg)
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
![](https://cdn.snapi.dev/images/v1/w/g/press20-2146281.jpg)
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh...
![](https://cdn.snapi.dev/images/v1/z/y/press12-2129703.jpg)
Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease
Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam's Cash Runway to the Second Half of 2026 Beam to Receive $250 Million in Combined Upfront Paymen...
![](https://cdn.snapi.dev/images/v1/e/z/press8-2119230.jpg)
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
Single Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year
![](https://cdn.snapi.dev/images/v1/v/a/biotech4-2111157.jpg)
Beam Therapeutics to cut 20% of workforce as part of restructuring plan
Beam Therapeutics said on Thursday it plans to reduce its headcount by about 100 employees, or 20% of its current workforce, as part of a restructuring plan.
![](https://cdn.snapi.dev/images/v1/m/c/biotech3-2111070.jpg)
Beam Therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026
Beam Therapeutics Inc. BEAM, -6.60% said Thursday it will reduce headcount by 100 employees, or about 20% of its workforce, to help it extend its cash runway into 2026. The Cambridge, Mass.
![](https://cdn.snapi.dev/images/v1/g/v/press19-2111037.jpg)
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation
![](https://cdn.snapi.dev/images/v1/z/e/press16-2053800.jpg)
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models First Preclinical Data for BEAM-302 Demonstrate I...
![](https://cdn.snapi.dev/images/v1/g/f/press5-2048809.jpg)
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States BEAM-201 Represent...
![](https://cdn.snapi.dev/images/v1/q/c/conf6-2044358.jpg)
Beam Therapeutics to Participate in Upcoming September Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
![](https://cdn.snapi.dev/images/v1/l/l/press7-2011349.jpg)
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort
![](https://cdn.snapi.dev/images/v1/q/x/conf11-1894532.jpg)
Beam Therapeutics to Participate in Upcoming May Investor Conferences
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that mana...